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Abstract.  Thrombospondin-1  (TSP1) is a large modu- 
lar matrix protein containing  three identical disulfide- 
linked  180-kD chains that inhibits neovascularization 
in vivo (Good et al.,  1990).  To determine which of 
the structural motifs present in the  180-kD TSP1 poly- 
peptide mediate the anti-angiogenic  activity, a  series of 
protease-generated fragments were tested using several 
in vitro and in vivo assays that reflect angiogenic ac- 
tivity. The majority of the anti-angiogenic  activity of 
TSP1  resides in the central 70-kD stalk region which 
alone could block neovascularization induced by bFGF 
in the rat cornea in vivo and inhibit both migration  in 
a modified Boyden chamber and [~H]thymidine incor- 
poration stimulated by bFGF in cultured capillary en- 
dothelial cells. Although TSP1 has been shown to bind 
active TGF/31,  this cytokine could not account for the 
inhibitory effects of the stalk region of TSP1  on cul- 
tured endothelial cells. 
Peptides and truncated molecules were used to fur- 
ther localize inhibitory activity to two domains of the 
central  stalk, the procollagen homology region and the 
properdin-like type 1 repeats.  Trimeric recombinant 
TSP1  containing  NH2-terminal  sequences truncated 
after the procollagen-like module inhibited endothelial 
cell migration  in vitro and corneal neovascularization 
in vivo whereas trimeric molecules truncated before 
this domain were inactive as was the NH2-terminal 
heparin-binding  domain that is present in both recom- 
binant molecules. A  series of peptides from the 
procollagen-like region, the smallest of which con- 
sisted of residues 303-309 of TSP1,  inhibited angio- 
genesis in vivo in the rat cornea and the migration of 
endothelial cells in vitro.  A  19-residue peptide con- 
taining these sequences blocked vessel formation in 
the granulation  tissue invading a polyvinyl sponge im- 
planted into the mouse. Nineteen residue peptides de- 
rived from two of the three type 1 repeats present in 
the intact TSP1 molecule blocked neovascularization in 
vivo in the rat cornea and inhibited the migration of 
cultured endothelial cells with EDs0'S of 0.6-7 #M. 
One of these peptides,  containing  residues 481-499 of 
TSP1,  also inhibited vessel formation in granulation 
tissue invading  sponges in vivo. 
These results suggest that the large TSP1 molecule 
employs at least two different structural domains and 
perhaps two different mechanisms to accomplish a  sin  2 
gle physiological function, the inhibition of neovascu- 
larization.  The definition of short peptides from each 
of these domains that are able to block the angiogenic 
process may be of use in designing targeted inhibitors 
of the pathological neovascularization that underlies 
many diseases. 
T 
rm  growth of new blood vessels in adult organisms 
is rare in most tissues in the absence of wounding or 
disease.  Although  potent angiogenic  factors able to 
stimulate new vessel growth can be isolated from many tis- 
sues (Folkman  and Klagsbrun,  1987),  they are ineffective 
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under normal physiological  conditions,  due in part to the 
presence of  molecules that antagonize them and act to inhibit 
angiogenesis  (Bouck, 1990; Klagsbrun and DAmorel 1991; 
Folkman and Shing, 1992). One molecule that is particularly 
well positioned to play an active physiological role in main: 
taining  the quiescence of vessels is thrombospondin.  It is 
both a constituent of the matrix that surrounds mature ves- 
sels and a potent inhibitor of neovascularization  (Good et al., 
1990). 
Thrombospondin-1  (TSP)~ is a 450-kD trimeric molecule 
1. Abbreviation  used in this paper:  TSP, thrombospondin. 
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in platelet alpha granules and is secreted by a wide variety 
of other cells including endothelia and is incorporated into 
their matrix (for review see Lawler,  1986;  Frazier,  1987; 
Asch and Nachrnan,  1989;  Mosher,  1990;  Frazier,  1991; 
Bornstein, 1992). TSP can mediate cell-cell interactions, in- 
cluding the attachment of malarial organisms and cells in- 
fected by them to endothelial cells. It also plays a role in 
cell-substrate interactions. Many cells attach, spread, and 
migrate  on  insoluble  thrombospondin,  although  for  en- 
dothelial cells TSP can be anti-adhesive. Endothelial cells 
can attach to TSP, but they generally spread poorly (Lahav, 
1988; Taraboletti et al., 1990; Tuszynski et al., 1992) unless 
high calcium or DTT reduction have been used to expose the 
RGD site on TSP1 (Sun et al., 1992). When endothelial cells 
are spread on other substrates their focal contacts are broken 
by exposure  to  soluble TSP  (Murphy-Ullrich and Hook, 
1989;  Murphy-UUrich et al.,  1991). In addition, TSP can 
influence the growth of a variety of cell types. When applied 
to  endothelial  cells  it  inhibits  growth  (Bagavandoss  and 
Wilks, 1990; Taraboletti et al., 1990; Murphy-Ullrich et al., 
1992), an effect shown in one case to be due to active TGF/~ 
that had bound to and copurified with platelet TSP (Murphy- 
UUrich et al.,  1992). 
TSP was first identified as an inhibitor of angiogenesis 
when the amino acid sequence of an anti-angiogenic hamster 
protein whose secretion was controlled by a tumor suppres- 
sor gene (Rastinejad et al., 1989) was found to be similar to 
a sequence in human platelet TSP (Good et al., 1990). Genu- 
ine human TSP was then purified from platelets and shown 
to block neovascularization in vivo in the rat cornea as well 
as to inhibit the chemotaxis of capillary endothelial cells to- 
wards angiogenic factors in vitro (Good et al., 1990).  This 
inhibitory role for TSP in angiogenesis is supported by its 
presence adjacent to mature quiescent vessels and its ab- 
sence from actively growing sprouts both in vivo (O'Shea 
and Dixit, 1988) and in vitro (Iruela-Arispe et al., 1991); by 
the failure of some hemangiomas consisting of fast growing 
endothelial cells to make TSP (Sage and Bornstein, 1982); 
by the ability of  antibodies to TSP to increase endothelial cell 
cord formation in vitro (Iruela-Arispe et al., 1991); and by 
the dramatic downregulation of TSP mRNA in cultures of 
endothelial cells that are forming tubules (Canfield et al., 
1986). 
The current study was undertaken to determine which do- 
mains of the complex TSP molecule are responsible for its 
ability to block neovascularization.  Quite  recently it has 
been found that at least four different genes encode distinct 
TSP-like proteins (Bornstein, 1992; Lawler et al., 1993) and 
isoforms of TSP exist that may be attributed to alternate 
splicing (Frazier, 1991). The work reported here deals with 
the well defined prototype molecule, now called TSP1, that 
was originally purified from platelets and whose cDNA has 
been  cloned  from both  fibroblasts  and  endothelial cells 
(Hennessy et al., 1989; Lawler and Hynes, 1986). The TSP1 
protein  from platelets consists  of three  identical  180-kD 
subunits with NH2- and COOH-terminal globular domains 
connected by a central stalk. The stalk region contains (a) 
the cysteines that form inter-chain links and adjacent regions 
that promote tfimer formation; (b)  a  stretch of 96 amino 
acids  that  are  homologous  to  sequences  in  the  NH2- 
terminal domain of the proof-1 chains of Collagen I; (c) three 
type 1 repeats also found in proteins encoded by Plasmodium 
falciparum, properdin, and proteins C6 through C9 that are 
active in the complement cascade; and (d) three EGF-like 
type 2 repeats (see reviews cited above and Fig. 1). We have 
found that the anti-angiogenic activity of TSP1 resides in this 
central stalk region of the TSP molecule. It can be repro- 
duced by small peptides  derived either from the procol- 
lagen-like region or from the properdin-like type 1 repeats. 
These findings define two distinct domains of  the TSP1 mole- 
cule that mediate the same function and suggest testable hy- 
potheses for the mechanism by which TSP1 inhibits neovas- 
cularization. 
Materials and Methods 
General Reagents 
Recombinant bFGF  and TGF/~I  and antibodies against purified platelet 
TGF~ developed in the chicken or rabbit were purchased from R & D Sys. 
Inc. (Minneapolis, MN).  Monoclonal antibody A4.1 which recognizes an 
epitope on the stalk region of TSP1  was prepared as previously described 
(Prater et al.,  1991). 
Thrombospondin and Its Peptide Fragments 
Human thrombospondin-1 was purified from platelet releasate as described 
(Dixit et al.,  1984) and was digested with TLCK-treated chymotrypsin in 
10  mM  EDTA.  Fragments  were purified  by  gel  filtration and heparin- 
Sepharose affinity chromatography following exactly the methods described 
by Prater et al. (1991).  Individual fragments of TSP1, one consisting of the 
monomeric NH2-terminal heparin-binding domain of TSP (25 kD) and an- 
other containing two nested trimers from the central stalk region in a  1:1 
ratio, one migrating on SDS-PAGE reducing gels at 50 kD, and one at 70 
kD (50/70 kD), were characterized by silver-stained SDS-PAGE and West- 
ern blotting with a panel of anti-TSP monoclonal antibodies and were found 
to be free of intact TSP (Prater et al., 1991). A naturally occurring fragment 
of the hamster homologue of TSPI, a 140-kD monomer whose NH2 termi- 
nus corresponds to amino acid 293 of the human TSP1  (hamster 140-kD, 
Good et al., 1990) was purified from the serum free-conditioned media of 
cultured  hamster cells by published methods  (Rastiuejad  et al.,  1989). 
NH2-terminal trimers of TSP1  mmcated at residue 277 (TSP-277) or 381 
(TSP-381) were produced and purified using a baculovirus expression sys- 
tem by Sottile and Mosher as described (Sottile et al., 1991) and generously 
provided by them for this study. The relationship of all these fragments to 
the 180-kD TSP monomer is illustrated in Fig.  1. 
Peptides based on TSP amino acid sequences were synthesized by the 
Washington University Protein Chemistry Facility (Mark Frazier, technical 
director) using solid phase synthesizer (model 3804; Appl.  Biosystems, 
Inc., Foster City, CA) and purified by reverse phase HPLC as detailed in 
Prater et al. (1991).  To remove organic salts, peptides were dissolved in 1 
ram HC1, passed over a G50 gel filtration column and lyophilized. All pep- 
tides were characterized by amino acid analysis and sequencing. As indi- 
cated in the text, some cysteines in the TSP sequence were replaced by ala- 
nines and two COOH-terminal  arginines by lysines. The pro~(1) peptide 
was made in the same way at the Biotechnnlogy Center at Northwestern 
University. 
In Vitro Assays for Angiogenic Activity 
Bovine adrenal capillary endothelial cells were the kind gift of Dr. Judah 
Folkman, Harvard University. Cells were carried in DME with 10% donor 
calf serum (Flow Laboratories, McLean, VA) and 100 #g/ml endothelial 
cell mitogen (Biomedical Tecbnois. Inc.,  Stooghton, MA), and used be- 
tween passages 10 and 15. To measure migration, cells were starved for 24 h 
in DME containing 0.1%  BSA, harvested, suspended in DME with 0.1% 
BSA, and plated at 1.75  x  lift/well on the lower surface of a gelatinized 
0.5  ttm filter (Nucleopore Corporation,  Pleasanton,  CA) in an inverted 
modified Boyden chamber. Afar 1-2 h at 37°C during which time the cells 
adhere to the filter, the chamber was reinverted, test material was added to 
the top well, and the chamber incubated 3-4 h at 37°C to allow migration. 
Chambers were then disassembled, membranes fixed and stained, and the 
The Journal of Cell Biology, Volume 122,  1993  498 Figure  1.  The  relationship of 
various protein fragments and 
peptides  to  the  180-kD  sub- 
unit of thrombospondin 1 and 
its  previously  defined  do- 
mains. S-S indicates the posi- 
tion  of the  cysteine  residues 
that join three of these 180-kD 
subunits in the native trimeric 
TSPI  molecule.  Peptide frag- 
ments  containing  this  region 
are  also  trimeric  whereas 
fragments lacking  it  are  mo- 
nomeric.  Please  see  Table  1I 
for exact  sequences of small 
peptides. 
number of  cells that had migrated to the top of  the filter in 10 high-powered 
fields counted (Good et al., 1990). DME with 0.1% BSA was used as a nega- 
tive control and either bFGF (10 ng/ml) or conditioned media from angio- 
genie hamster cell lines (20 #g/mi total protein; Rastinejad et al., 1989) as 
a positive control. Each sample was tested in quadruplicate in a single ex- 
periment and experiments were repeated at least twice. To allow comparison 
of experiments performed on different days, migration data is reported as 
% of  maximum migration towards the positive control, calculated after sub- 
traction of background migration observed to DME plus BSA. Test com- 
pounds that depressed the random movement of endothelial cells showed 
a negative value for % migration when it was calculated in this way. Very 
high concentrations of TSP caused endothelial ceils to detach from the 
membrane. This was detected by counting cells on the lower face of the 
membrane. In the rare instances when loss of  cells exceeded 10%, the num- 
ber of migrated cells was corrected for this loss. Such instances are marked 
by * in Fig. 3. 
To monitor toxicity, endothelial cells were treated with each of  the tested 
compounds at a range of  concentrations that included the highest concentra- 
tion for which data is reported here, under conditions identical to those used 
in the migration assay and cells excluding Trypan blue counted. In no case 
could inhibition of migration be attributed to toxicity as measured in this 
way. When necessary, as noted in the text, endothelial cells were pretreated 
for 36--48 h with peptides at 20 #M in DME with 0.1% BSA before use in 
migration assays. In these cases toxicity was tested over a similar time frame 
and found to be negligible. 
Incorporation of [3H]thymidine followed by autoradiography was used 
to estimate the number of cells synthesizing DNA. Capillary endothelial 
cells  were  plated  at  5  ×  103  cells/0.25  ml  chamber  on  16-chamber 
gelatinized glass slides (Nunc, Naperville, IL) in complete media.  After 
24 h, the serum was lowered to 0.5% and incubation continued for 30 h. 
The cells were then incubated 30 h in serum-free media consisting of DME 
and Hanks F12  (1:1) with 1 mg/ml BSA and 5  #g/ml human transferrin 
(GIBCO BRL, Gaithersburg, MD). Test substances were then added to qua- 
drnplicate wells along with 1 #Ci/chamber of [3H]thymidine (Amersham 
Corp., Arlington Heights, IL) and cultures incubated at 37*C for 30 h. TSP1 
and its fragments were used at 40 nM, TGF/~ at 16 pM, and bFGF at 0.6 
nM.  Where indicated, anti-TGF/~ antibodies or anti-TSP1  antibody A4.1 
were added at a final concentration of 20 #g/ml. The assay was terminated 
by the addition of 2.5 % glutaraldehyde in PBS. Slides were treated for 30 
min with 0.1 M glycine, rinsed, and after air drying were coated with NTB2 
liquid emulsion (Kodak, Rochester, NY) diluted 1:1 with water, exposed for 
3 d at 40C, and developed in D-19 (Kodak). After counterstaining in Camco 
Quick Stain (Scientific Products, McGaw Park, IL), at least 400 nuclei were 
examined for each test substance and the percent nuclei labeled with more 
than 20 grains determined. 
In Vivo  Assays  for Angiogenic Activity 
To assess angiogenesis associated with the formation of granulation tissue, 
sponge implants were used as previously described (Fajardo et al., 1988). 
Polyvinyl-alcohol foam discs 10-mm diam x  l-ram thick were prepared by 
first removing a 2-ram diam central core of sponge. PBS or test peptidns 
at  100-/zM concentration were added to the sponge core which was then 
coated with 5 #1 of sterile Hydron (Interferon Sciences, New Brunswick, 
NJ).  After solidifying, the coated core was returned to the center of the 
sponge which was then covered on both sides with 5 #m filters and secured 
in place with glue (Millipore Corp., Bedford, MA). One control and one 
test disc were then implanted subcutaneously in the lower abdomen of 
anesthetized Balb/c female mice where granulation tissue could invade the 
free perimeter of the disc. Wounds were closed with autoclips and animals 
left undisturbed until time of sacrifice. 
Quantitative estimates of  thymidine incorporation in situ into endothelial 
cells in the discs were obtained as previously described (Polverini et al., 
1977). Sponge implants were evaluated at days 5, 7, 10, and 14 after implan- 
tation.  30  min  before  sacrifice,  mice  were  injected  with  1  #Ci/g  of 
[3H]thymidine in saline (specific activity 6.7 Ci/mM; New England Nu- 
clear/Du Pont, Wilmington, DE). Sponges were removed and embedded 
enface to provide a uniform section of the entire circumference. Tissues 
were fixed in 10% neutral buffered formalin, dehydrated through a graded 
series of alcohols, and embedded in glycol methracrylate (Polysciencos, 
Miles, IL). Autoradiograms were prepared by dipping sections mounted on 
acid-cleaned glass slides into NTIS type 2 emulsion (Eastman Kodak). After 
exposure for 4 wk at 4°C, autoradiographs were developed in half strength 
D-19 developer, fixed in Kodak Rapid Fixer, and stained with hematoxylin 
and eosin. Quantitation of  endothelial cell labeling was performed  by count- 
ing all endothelial cells lining capillaries and venules that extended from 
the periphery to the center of the sponge by rectilinear scanning under oil 
immersion (xI,000). A total of 500-700 endothelial cells were counted in 
each of  two sponges  containing either PBS, TSP, or peptide fragments. Cells 
were considered labeled if five or more grains were detected over the nu- 
cleus. The percentage of  labeled ceils was calculated and a chi square analy- 
sis of data derived from control and experimental sponges performed. 
The ability of  experimental samples to induce and/or inhibit neovaseular- 
ization in the normally vascular cornea of  the rat was also assessed as previ- 
ously described (Rastinejad et al.,  1989;  Polverini et al., 1991). Briefly,  a 
pellet of  less than 5 #1 was formulated containing test ingredients in hydmxy- 
ethylmethacrylate (Hydron  R) and implanted 1-1.5 mm from the limbus of 
the cornea of the anesthetized rat.  Neovascularization was assessed (Pol- 
verini et al.,  1991) 3,  5,  and 7  d  after implantation.  To photograph re- 
sponses, animals were perfused with colloidal carbon to label vessels and 
corneas were excised, flattened, and photographed. 
Results 
Localization of  Anti-Angiogenic Activity to the Stalk 
Region of TSP1 
To determine which domains of  the TSP1 molecule can block 
neovascularization, purified platelet TSP1 was digested with 
chymotrypsin in the absence of  calcium and fragments corre- 
sponding to the 25  kD NH2-terminal heparin-binding  do- 
main and to the nested 50 and 70 kD portions of the stalk 
region were isolated. In addition, the foreshortened hamster 
protein,  gpl40 (Rastinejad et al.,  1989) that represents the 
COOH-terminal  140 kD of TSP1 (Good et al.,  1990) was 
prepared.  The position of these fragments within the whole 
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platelet releasates was digested with TLCK-treated chymotrypsin 
and proteolytic fragments isolated. In addition, the foreshortened 
fragment of  TSP1 produced by Syrian hamster cells, gpl40, was iso- 
lated from conditioned media. Proteins and fragments were run on 
an SDS-PAGE  gel and stained with Coomassie  blue. (a) total digest 
of TSP1; (b) purified 25-kD fragment; (c) purified 50/70-kD frag- 
ment~ (d) purified hamster gp140; and (e) human platelet throm- 
bospondin  1. 
molecule is indicated in Fig. 1 and has been verified by data 
presented elsewhere (Good et al.,  1990; Prater et al.  1991). 
The comparative mobility of these fragments on gels is shown 
in Fig. 2. Each of the protein fragments was tested for ability 
to induce and/or inhibit neovascularization in vivo in the rat 
cornea (Table I). None of the preparations stimulated neo- 
vascularization when tested alone. All of the chymotryptic 
fragments except the NHz-terminal 25 kD heparin-binding 
region  blocked  neovascularization  in  response  to  bFGF, 
localizing the anti-angiogenic activity to the 50/70 kD stalk 
region. An example of  inhibition of bFGF-induced neovascu- 
larization by the stalk region alone in the rat cornea is shown 
in Fig. 3  B. 
To observe the activity of each protein fragment directly 
on endothelial cells in the absence of the accessory cells that 
are unavoidable in vivo and to quantitate their relative poten- 
cies, an in vitro migration assay was used.  The ability of a 
compound to induce or inhibit the migration of cultured cap- 
illary endothelial ceils in vitro has been found to correlate 
well with its ability to induce or suppress neovascularization 
in vivo (Zetter, 1987; Folkrnan and Klagsbrun, 1987; Klags- 
brun and D~'nore,  1991).  When tested alone at concentra- 
tions of 5 nM or less, no TSP1 fragments were able to stimu- 
late the migration of endothelial cells (Fig. 4 a),  reflecting 
their inability to induce neovascularization in vivo (Table I). 
But when higher concentrations were tested in vitro, both the 
entire TSP1 molecule and the 25-kD fragment containing the 
heparin-binding  domain  stimulated  migration.  Fragments 
lacking this domain, including the 50/70-kD fragment and 
the hamster gpl40 (data not  shown),  remained inactive at 
concentrations up to 600 nM. The stimulatory activity of the 
25-kD  fragment  is  due  to  the  stimulation  of  random 
chemokinesis rather than of directed chemotaxis for migra- 
tion into the upper well of the Boyden chamber was stimu- 
lated equally if the 25-kD fragment was added to the upper 
well,  the  lower well,  or  to  both wells  (data  not  shown). 
Taraboletti et al. (1990,  1992) have also reported a dramatic 
stimulation of migration by intact TSP at high concentrations 
Table I.  The Effect of Protein Fragments of 
Thrombospondin on Corneal Neovascularization 
Protein 
fragment 
tested 
Positive corneas/number  implanted 
Alone  + Inducer 
None  0/4  4/4 
TSP  0/5  0/5 
TSP 
chymotryptic digest  0/6  0/3 
140 kD (from hamster)  0/8  0/5 
50/70 kD  0/7  0/5 
25 kD  0/6  5/6 
TSP-277  0/3  3/3 
TSP-381  0/5  0/4 
Hydron  pellets  containing TSP1 protein  or its various  fragments  at 25-30 nM 
were formulated  either with or without bFGF as an inducer at 0.15 /~M and 
implanted into rat corneas. Vigorous  vessel ingrowth from  the limbus at 7 d 
was recorded as a positive response (see Fig. 3 A). 
and have localized this activity to the heparin-binding do- 
main, represented here by the 25-kD fragment. 
When the same protein fragments were tested for ability 
to block endothelial cell migration stimulated by bFGE the 
results were similar to those observed in vivo. The 25-kD 
peptide was ineffective, but complete inhibition was obtained 
with the 50/70 fragment and with intact TSP1 (Fig. 4 b). The 
total unfractionated digest and hamster 140-kD protein were 
also tested over a  similar concentration range and also in- 
hibited  migration,  with an ED~o of 1.1  nM  for the  digest 
and 0.7 nM for hamster 140 kD, values similar to the ED~o 
of 0.9 nM seen with the 50/70-kD fragment. The 50/70 frac- 
tion differed in two days from the intact TSP1  molecule. At 
low concentrations it was not quite as potent an inhibitor as 
TSP1, possibly due to its lack of the heparin-binding domain 
which  can mediate the attachment of TSP1  to endothelial 
cells (Murphy-Ullrich and Mosher,  1987).  At high concen- 
trations,  the  50/70  fragment remained inhibitory whereas 
the intact TSP1  induced migration. This difference can also 
be attributed  to the heparin-binding  domain which,  when 
isolated as the 25-kD fragment, is a potent inducer of migra- 
tion at high concentrations (Fig. 4  a). 
These data suggest that the ability of TSP1 to inhibit neo- 
vascularization in vivo and endothelial cell migration in vitro 
lies primarily in the stalk region of the TSP1  molecule. To 
further  localize the  residues  responsible  for this  activity, 
peptides from two different stalk domains were synthesized 
and tested. 
Peptides Derived from the Properdin ~jpe 1 Region of 
TSP1 Can Inhibit Neovascularization 
The properdin-like repeat region  1 of the  TSP1  molecule 
contains a  sequence of ,~60 residues that is repeated three 
times. Each repeat is ~47 % identical to six similar repeats 
found in the human complement protein properdin and to re- 
gion II of a circumsporozoite protein common to all species 
of malaria parasites (Robson et ai., 1988; Goundis and Reid, 
1988). Protein fragments of TSP containing these repeats as 
well as peptides derived from them can serve as attachment 
factors for melanoma cells and for endothelial cells (Prater 
et al.,  1991; Guo et al.,  1992; Tuszynski et al.,  1992).  The 
The Journal of Cell Biology, Volume 122, 1993  500 Figure 3. The effect of fragments and peptides derived from TSP1 on neovascularization induced in vivo in the rat cornea by bFGF. Hydron 
pellets were formulated as described in legend to Tables I and IH and implanted into corneas of rats. 7 d later animals were perfused ~vith 
colloidal carbon, corneas excised and vessels in the region of the pellet implant photographed.  Pellets contained (A) bFGF; (B)' bFGF 
+  50/70 kD fragment of TSPI; (C) bFGF +  Mal I peptide;  (D) bFGF +  Mal II peptide;  (E) bFGF +  Mal III peptide; or (F) bFGF 
+  Col 1 peptide. 
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most active of these peptides has a central motif, VTCG, that 
has been shown to be essential for the adhesion of malarial 
circumsporozoite proteins to human  T  cells  (Rich  et al., 
1990). To determine if these cell-binding domains from the 
type 1 repeats of TSP have an effect on angiogenesis, peptides 
from each were synthesized (Mal peptides, Fig.  1 and Table 
II) and tested for their ability to block neovascularization in 
vivo. 
In  formulating  these  Mal  peptides,  alanines  were  sub- 
stituted  for  cysteines  in  part  because  it  is  not  yet  clear 
whether the two cysteines in each Mal peptide are paired 
with one another or with cysteines located elsewhere in the 
molecule, and in part to avoid the formation of polymers un- 
der the oxidizing conditions of our assay. Free cysteines have 
clearly been shown to be dispensable when similar peptides 
serve as cell  adhesion  factors  (Prater  et al.,  1991),  bind 
CD36  (Asch  et  al.,  1992),  or block platelet  aggregation 
(Tuszynski et al.,  1992).  Data reported below indicate that 
they  are  not  essential  for  the  inhibition  of angiogenesis 
either. 
Mal peptides derived from the second and third type  1 
repeats were able to block neovascularization in vivo in two 
different assays. In the rat cornea assay, Mal II and Mal III 
inhibited  neovascularization  induced  by  bFGF  whereas 
structurally similar Mal I was inactive (Table 111; Fig. 3, C, 
D,  and E).  In a  second in vivo assay,  Mal peptides were 
tested for their ability to influence the  neovascularization 
that  accompanies  the  formation of the  granulation  tissue 
characteristic of a healing wound. Polyvinyl sponges about 
the size of a dime that were open only around their circum- 
ference were constructed with central pellets containing pep- 
37°C. Data is reported as % of maximum migration summed over 
five experiments.  100% varied between experiments from 79 to 
209 cells migrated/10 high-powered fields. At high concentrations 
intact TSP1 caused endothelial cells to detach from the membrane. 
Points marked with * are derived from wells where more than 10% 
of the cells detached and they have been corrected for this cell loss. 
Bars indicate SEM. 
Table IL Peptide Sequences Employed in Analysis 
Peptides from type 1 repeats of TSP1 
Mall  SEWTSC*STSC*GNG  I  QQRGK 
MallI  S PWSSC*SVTC*G  DGV  I  TR  I  R 
Mal III  SPWD  I  C*SVTC*GGGVQKRSK 
Mal overlap  D  I  C*S V T C G 
Peptides from the procollagen homology region of TSP1 
Col 1,  (L) RRPPLCYHNGVQYRNNEEWTVDS 
N-Col  L  RRPPLCYHNGVQYR 
C-Col  GVQYRNNEEWTVDSC 
Col overlap  N G V Q Y R N 
Scrambled Col overlap  R Q G N Y V N 
Peptide from collagen I 
Protx  1 
Control peptides 
YEGKK 
NYlong 
N  I  PP  I  TC*VQNGLRY 
YEGKK 
ADSGP  I  YDKTYAGGRLG 
ResCues 
368-386 
424-442 
481-499 
484-491 
294-317 
294-308 
304-318 
303-309 
303-309 
(scrambled) 
34--47§ 
1108-1112 
1115-1131 
* Indicates those cysteines that were replaced by alanine when peptides were synthesized. 
$ 90%  preparation missing first L. 
§ Peptide derived from human prowl(I) collagen sequence (Chu et al.,  1984). 
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Peptides on Corneal Neovascularization 
Positive corneas/number implanted 
Peptide alone  Peptide  +  inducer 
Peptides from repeat region  1 
Mal I  0/4  3/4 
Mal II  0/5  0/4 
Mal III  0/4  0/11 
Peptides from procollagen like region 
Col  1  0/3  0/4 
N-Col  0/8  0/3 
C-Col  0/3  0/4 
Col overlap  0/3  0/8 
Scrambled Col overlap  0/3  3/3 
Pro a-1  0/3  0/7 
Controls 
TSP-  1  0/5  0/4 
buffer  0/4  6/6 
NYlong  0/6  3/3 
Hydron pellets containing peptides at concentrations ranging between 100-500 
tiM with or without bFGF as an inducer at 0.15/~M were implanted into rat 
corneas and neovascolarization assessed 7 d later. NYlong, a peptide from the 
COOH-terminal region of TSP, served as a negative control. 
tide and implanted into mice. The presence of TSP1  in the 
central pellet significantly decreased the number of vessels 
present  in  the  sponge  implant  (Fig.  5).  This  effect was 
quantified by in vivo labeling with [3H]thymidine followed 
by autoradiography and counting of labeled endothelial cells 
(Table IV). Both TSP1 and the Mal III peptide significantly 
decreased the number of thymidine-labeled endothelial cells 
present in the sponges at days 10 and  14.  As in the cornea 
assay, Mal I was inactive. The effect  ofMal II was not statisti- 
cally significantp value of 0.001 (Table IV), but did show in- 
hibition at  day  14  that  was  significant at  a  less  stringent 
p  value of 0.05. 
To compare the Mal peptides to one another quantitatively 
away from the complex environment present in vivo, exten- 
sive dose response curves were performed using the ability 
to block migration of cultured endothelial cells as an assay. 
Each peptide was tested over a range from 0.5 or 5/zM to 
200 or 500 #M,  stopping where toxicity became evident. 
From  the  resulting  dose  response  curves  containing  5-7 
points, the concentration required to achieve half maximal 
response was calculated. None of the peptides induced en- 
dothelial cell migration when tested alone (Table V). When 
tested with inducer, the two peptides that inhibited neovascu- 
larization in the rat cornea were found to block cell migra- 
tion. The Mal I peptide that was inactive in vivo was also in- 
active in vitro. The conditioned media used as an inducer in 
Table V contained low levels of gpl40, the shortened hamster 
version of TSP1  (Rastinejad et al.,  1989). This protein had 
no  effect on the  EDso. When  retested using  pure recom- 
binant bFGF as an inducer, Mal III inhibited migration with 
an ED~0 of 7 #M.  This value and those obtained in parallel 
for non-inhibitory peptides were similar to values reported 
in Table V. A shorter peptide containing the central region 
shared by inhibitory peptides Mal II and Mal HI was synthe- 
sized (Mal overlap, Table II), but was inactive in the migra- 
tion assay (Table V). 
Figure 5. Neovascularization associated with wound healing is se- 
verely limited by TSPI. Enface sections through polyvinyl sponges 
recovered 10 d after implanting in the mouse were photographed 
midway between central pellet and periphery of  the sponge disc. (A) 
Sponge containing central pellet formulated as in legend to Table 
I containing TSP1. Note the presence of inflammatory cells but the 
absence of organized capillaries. (B) Sponge containing a central 
pellet containing buffer. Note luxuriant ingrowth of new vessels. 
S indicates sponge material;  arrows mark  some of the  vessels. 
Magnification 225 ×. 
Peptides Derived from the Procollagen Homology 
Region of TSPI Block Neovascularization 
The procollagen-like region of TSP1  consists of "~90 resi- 
dues, including 10 cysteines, that are homologous to the 10.7- 
kD propeptide that is cleaved from the NH2 terminus of hu- 
man  collagen  I  during  maturation  of the  collagen  fibril 
(Vuorio and de Crombrugghe, 1990). This collagen propep- 
tide can selectively downregulate synthesis of the prood and 
proof2 chains of collagen I (Wiestner et al.,  1979). The fact 
that many diverse inhibitors of  angiogenesis have in common 
the ability to interfere with collagen synthesis and/or deposi- 
tion (Ingber and Folkman, 1988; Maragoudakis et al., 1988) 
led us to test the procollagen homology region of TSP1 for 
inhibitory activity. A series of peptides (Col peptides, Table 
II) were synthesized and tested. 
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% Thymidine-labeled  endothelial cells 
Day after 
implantation  PBS control  TSP  Mal I  Mal II  Mal IIl  NYLONG  YEGKK  Col l 
5  3.84  ±  1.15  2.27  ±  1.89  4.23  ±  2.01  5.01  ±  1.11  2.11  ±  0.98  2.99  +  1.99  4.55  +  2.48  2.98  +  2.35 
7  5.36  ±  0.56  1.98  ±  2.18  6.17  ±  1.11  6.15  ±  2.17  2.38  ±  1.98  3.25  ±  2.75  7.19  ±  3.29  3.29  +  1.18 
10  8.13  ±  1.38  3.76  ±  2.08*  8.89  ±  2.39  8.81  +  2.10  4.47  ±  2.39*  7.38  ±  2.29  10.18  ±  2.54  4.89  ±  2.15" 
14  13.67  ±  2.25  7.49  +  2.10"  12.18  ±  2.66  10.21  +  1.19  6.19  ±  1.79"  14.92  +  3.65  15.16  ±  3.08  7.88  ±  3.38* 
One-half  centimeter diameter, 1-mm  thick discs of polyvinyl sponge were modified  to release test substances  from pellets at their center and implanted subcutane- 
ously in the lower abdomen of Balb/c female mice. Animals were given a 30-min pulse of [3H]thymidine before being sacrificed on various days after implanta- 
tion. Thymidine incorporation by endothelial cells lining capillaries and venules were counted on autoradiograms. Values reported are means +SD. 
* Significantly different (P < 0.001) when compared to controls. 
The 24 residue Col 1 peptide as well as overlapping pep- 
tides from its NH2 and COOH terminus and a short 7-resi- 
due peptide from the central overlap region were all able to 
block neovascularization in vivo in the rat cornea (Table HI; 
Fig. 3 F). When the sequence of the seven amino acids in 
the Col overlap peptide was scrambled, activity was lost. 
The large Col 1 peptide was also effective at inhibiting angio- 
genesis in vivo in the sponge model (Table IV). 
Despite their in vivo activity, the Col peptides were inac- 
tive when they were first tested in vitro for ability to inhibit 
endothelial cell migration. Reasoning that the time frame of 
the migration assay,  where endothelial cells are exposed to 
inducers and/or inhibitors for only 3-4 h may be too short 
to register the effect  of inhibitors that are working by indirect 
means, such as regulation of other secreted molecules, the 
assay was  modified.  Endothelial cells were pretreated for 
36-48 h with peptide, and then harvested, plated into migra- 
tion assay in a Boyden chamber, and their ability to migrate 
towards an inducer in the presence or absence of test pep- 
tides measured. The effect of peptides alone was also exam- 
ined. Assayed in this way all the Col peptides that were active 
inhibitors in vivo in the rat cornea were able to inhibit migra- 
tion towards bFGF in vitro (Figs. 6 and 7). The scrambled 
peptide was inactive in vitro as it had been in the cornea. 
Pretreatment by the Col 1 peptide but not by a control pep- 
tide  could  sensitize the  endothelial  cells  to  inhibition  of 
migration by other Col peptides. Inhibition by the Mal HI 
ED~o for endothelial cell migration (/zM) 
Induction of migration 
Peptide alone 
Inhibition of migration 
Peptide +  inducer 
Cells Pretreated With 
Control Peptide 
TSP  0.01  0.0002 
Mal I  >100  >100 
Mal II  >300  0.6 
Mal IN  >400  5 
Mal overlap  >200  >200 
NYlong  >400  >400 
The ability of peptides to induce migration of capillary endothelial cells was 
measured  by estimating  from dose response curves the concentration  in/zM re- 
quired to stimulate migration of endothelial cells by 50% of maximum. The 
ability of peptides to inhibit migration was measured by estimating from dose 
response  curves the dose required to reduce capillary endothelial  cell migration 
toward inducer by 50%. Inducer used was angiogenic  conditioned  media from 
transformed  hamster cells. NYlong, a peptide from the COOH-terminal  region 
of  TSP1 served as a negative  control. When no effect  was observed, the > sym- 
bol was used to indicate the highest concentration  at which it was possible to 
test each peptide within the limits of toxicity and solubility. 
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Figure 6. The effect of peptides from the procollagen homology re- 
gion of thrombospondin  on endothelial cell migration. Endothelial 
cells were pretreated for 36-48 h with control peptide (Mal I) or 
with Col  1 peptide at 20/zM, and then harvested and tested in a 
migration assay (as described in legend to Fig. 4) for ability to mi- 
grate to a chamber containing various peptides at 20/LM either with 
or without an inducer, bFGF at 10 ng/ml. Peptides used were (a) 
none, (b) Mal I, (c) Mal IN, (d) Col 1, (e) N-Col, (F) C-Col, and 
(g)  Procxl. Data is reported as  %  maximum migration to bFGF 
where 100% varied from experiment  to experiment  between 60 and 
146 cells migrated/10 high power fields. Negative percentages re- 
flect an inhibition of the random movement of endothelial cells. 
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Figure 7. The effects of protein fragments and a seven amino acid 
peptide from the procollagen like region of the thrombospondin on 
endothelial cell migration. Experiment performed as in Fig. 6. En- 
dothelial cells were either not pretreated, or were pretreated with 
the collagen overlap peptide or with a peptide derived from its 
scrambled sequences, and then tested for ability to migrate in the 
presence or absence of inducer (bFGF) to wells containing (a) no 
added peptide, (b) collagen overlap peptide, (c) scrambled amino 
acids from the collagen overlap peptide, (d) TSP-277, or (e) TSP- 
381. Peptides were used at 25 #M, fragments at 5 nM; pretreatment 
was for 48 h. 
peptide did not require such sensitization (Fig. 6 c) and sen- 
sitization was not sufficient to allow the inactive Mal I pep- 
tide to inhibit migration (Fig. 6 b). In additional experiments 
not shown it was  found that both C-Col and N-Col were 
effective at sensitizing cells. Only the Col overlap peptide 
was able to significantly reduce migration without pretreat- 
ment of endothelial cells although pretreatment did increase 
its effectiveness (Fig. 7 b). 
To determine if the homology between the procollagen re- 
gion of TSP1  and the propeptide of authentic collagen I is 
functionally significant, a peptide was synthesized based on 
the published sequence of human procd(I) collagen that cov- 
ered that region homologous to the Col 1 peptide. This pep- 
tide (prootl, Table II) was found to inhibit neovascularization 
in the rat cornea in vivo (Table III) and to block migration 
towards bFGF in vitro when cells were pretreated with Col 
1 (Fig. 6 g) or with the Prood peptide itself(data not shown). 
Seeking evidence that the region of TSP1 from which the 
Col peptides are derived is exposed and thus active when 
TSP is  in its native conformation, recombinant truncated 
TSP1 molecules secreted by insect cells were tested, one of 
which  contained the  procollagen homology region  (TSP- 
381, truncated at amino acid 381) and one of which was lack- 
ing it (TSP-277,  truncated at amino acid 277). The TSP-381 
protein includes part of the inactive Mal I region, but none 
of the active Mal II or Mal III regions of the type 1 repeats. 
Both of the truncated proteins assume the trimer configura- 
tion  characteristic of the  native  molecule  (Sottile  et  al., 
1991). When tested in vivo in the cornea assay (Table I) as 
well as when tested in vitro for ability to block endothelial 
cell migration (Fig. 7, d and e), only the fragment that re- 
tained the procollagen-like region was able to inhibit, sug- 
gesting that this region is exposed in this glycosylated ver- 
sion of the native tfimeric molecule. In contrast to most Col 
peptides, TSP-381 could inhibit migration efficiently without 
pretreatment of the endothelial cells (Fig. 7 e). Unlike the 
peptides, TSP-381 does have a trimeric heparin-binding do- 
main that may facilitate its interaction with cultured cells. 
The In Vitro Anti-Angiogenic Activity of the 50/70 
Stalk of TSPI Is Not Due to Contaminating TGF~ 
It has recently been shown that active TGF~ can bind to and 
copurify with TSP (Murphy-Ullrich et al., 1992), raising the 
possibility that contaminating "I'GF/3 could be responsible 
for a portion of the anti-angiogenic activity of intact TSP and 
its fragments. Although TGF/~ is usually found to induce an- 
giogenesis  when  tested  in  vivo  (Rastinejad  et  al.,  1989; 
Roberts and Sporn, 1989; Yang and Moses, 1990), it can in- 
hibit a number of endothelial cell functions in vitro, includ- 
ing endothelial cell mitogenesis, migration, proteolysis, and 
tube formation (Muller et al.,  1987;  Roberts and  Sporn, 
1989; Pepper et al., 1990). Two separate preparations of the 
purified TSP1 used in this work were tested in a bioassay for 
the presence of active TGF/3 by Dr. Joanne Murphy-Ullrich 
of the University of Alabama at Birmingham and found to 
contain 0.96-2.8 fmol of active TGF/3 per 2.2 pM of TSP1 
trimer, or about one molecule of TGF/~ for every 1,000 mole- 
cules  of  TSP1  (Murphy-UUrich,  J.,  personal  communi- 
cation). 
Two in vitro assays were used to test whether or not this 
small amount of TGF/3 played a role in the anti-angiogenic 
activity of TSP1. To test the influence of'l'GF/$ on the migra- 
tion assay, an extensive TGF/~ dose response curve was gen- 
erated (Fig. 8). At very low doses of <10 pg/ml TGF/3'I in- 
duced  endothelial  cell  migration  and  this  induction  was 
additive with that  stimulated by bFGE  At concentrations 
above 10 pg/mi, as has been observed previously (Muller et 
al.,  1987),  TGFB1  inhibited  endothelial cell  migration. 
Similar biphasic responses have been seen for TGF/3 effects 
on  the  induced  growth  of small  vessel endothelial  cells 
(Plouet and Gospodarowicz,  1989;  Myoken et al.,  1990). 
The concentration of anti-TGFb'l antisera sufficient to block 
both the inducing and inhibitory effects of TGF~I was deter- 
mined, and then the ability of antibodies used at this concen- 
tration to relieve inhibition of migration caused by TSP1 was 
tested. Antibodies able to neutralize the effects of TGF# had 
no effect on inhibition of migration by TSP1  (Table VI). 
As the biological effect of TSP-associated-TGF/~  was first 
detected using a mitogenesis assay (Murphy-Ullrich et al., 
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Figure 8. The induction and the inhibition of  endothelial cell migra- 
tion by TGFfll. Methods as in legend to Fig. 4.  100% migration 
was taken as the maximal migration in response to TGFfll and is 
equivalent to an average of 138 cells migrated/10 high-powered 
fields. 
1992),  the ability of TSP1  and  its  fragments to  influence 
bFGF-stimulated  pH]thymidine  incorporation  into  capil- 
lary endothelial cells was also examined (Fig. 9). The inhibi- 
tion of [3H]thymidine incorporation by TSP1  in this assay 
was similar to the inhibition of cell proliferation by TSP1 
previously reported by Murphy-UUrich et al. (1992) in that 
it was reversible partially by anti-TGFfl andpartially by anti- 
TSP1.  However, inhibition by the 50/70-kD stalk fragment 
of TSP1 was insensitive to anti-TGFfl and fully reversed by 
anti-TSP1,  suggesting that inhibition by the stalk region of 
TSP1 is not due to associated TGFB. A modest reduction in 
the number of nuclei incorporating thymidine was seen in the 
presence of  the 25-kD fragment of  TSP1. This fragment lacks 
the epitope recognized by the anti-TSP1  monoclonal used 
and was insensitive to both this antibody and to anti-TGF~. 
Discussion 
TSP1  and peptides derived from two distinct regions of its 
central 70 kD stalk were able to block the growth of new 
blood vessels in two in vivo systems. In the rat cornea assay, 
considered the gold standard in the field, TSP1, the 50/70- 
kD stalk and peptides derived from it inhibited new vessels 
that are induced to grow into the normally avascular cornea 
in the absence of inflammation. TSP1 and its peptides also 
prevented neovascularization in the polyvinyl sponge assay, 
a model of normal wound healing where new vessels grow 
into the sponge material without added inducer in response 
to natural inflammatory signals as part of healing granula- 
Table  VI.  Inhibitory Activity  of Thrombospondin  on 
Endothelial  Cell Migration Is Not Sensitive to Neutralizing 
Antiserum against  TGFfl 
Migration  of endothelial  cells to 
upper chamber (%) 
Additions to 
upper chamber  Control  +  anti-TGFfl 
None  <1  -t-  15  10  +  16 
TGFfl  (1  pg/ml)  98  -t-  17  <1  +  17 
bFGF (10 ng/ml)  100  +  17  94  -1-  19 
bFGF  +  TGFfl (0.2  ng/ml)  28  -I-  16  79  -t-  16 
bFGF  +  TSP (2.5/~g/ml)  <1  +  15  <1  +  18 
Figure 9. Inhibition of the incorporation of  thymidine into capillary 
endothelial cells by the  stalk  region of TSP1 is independent of 
TGFfl. Capillary endothelial cells were starved, incubated for 30 h 
in quadruplicate with the indicated test substances in the presence 
of [3H]thymidine,  and the % labeled nuclei determined after auto- 
radiography, bFGF was used as an inducer at 0.6 nlVl, TGFfll was 
present at 16 pM, and TSP1 and its fragments at 40 nM. Data from 
one of  three similar experiments is presented. An independent t test 
showed that the number of labeled nuclei was significantly different 
(P < 0.05) from the number labeled in the relevant positive control 
(media +  inducer) for all samples tested except those where the 
effects of TGFfl and the 50/70-kD stalk of TSPI were blocked by 
anti-TGFfl and anti-TSP, respectively. 
tion tissue. The fact that TSP1 and its derivatives were also 
inhibitory in in vitro assays using isolated cultured capillary 
endothelial ceils suggests that they may inhibit in vivo by in- 
teracting directly with the endothelial cells. In these in vivo 
assays it is not yet clear how the large, "sticky" TSP1 mole- 
cule can diffuse from the pellet to nearby vessels rapidly 
enough to prevent activation of the angiogenic response. It 
may well be broken down by proteolysis into smaller, more 
mobile, active fragments after implantation. 
It is quite remarkable that the small peptides derived from 
TSP1 are active in these in vivo assays that allow prolonged 
exposure of the peptides to physiological fluids. The activity 
of the  peptides  suggests  that  they may  have a  very high 
affinity for whatever receptors they interact with on the en- 
dothelial cell. The two in vivo assays correlated well, with 
the exception of Mal II which blocked neovascularization in 
the cornea, and migration in vitro, but showed only border- 
line  activity  in  the  sponge,  although  the  Mal  HI peptide 
which is composed of very similar residues was very effec- 
tive in all assays.  This discrepancy might be explained by 
differential sensitivity of these two peptides to proteases en- 
countered in vivo in the sponge. The sponge assay not only 
requires a longer time in vivo than the cornea assay, but also 
exposes the peptide to products of migrating fibroblasts and 
inflammatory cells that are abundant in the sponge environ- 
ment but rare in the cornea assay. Mal II but not Mal III con- 
tains a central aspartic acid residue that can be a cleavage site 
for several bacterial proteases  that  cleave at  glutamic  or 
aspartic acid residues (Kakudo et al.,  1992, and references 
therein).  Endoprotease activities with  similar specificities 
have  been  identified  in  mammalian  inflammatory  cells 
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the possibility that such proteases, to which Mal II might be 
particularly  sensitive,  are  present  in  the  inflammatory 
wound environment of the sponge and may account for the 
failure of Mal II to block vessel formation efficiently in this 
assay. 
In vitro assays with cultured endothelial cells are designed 
to dissect out and assay separately the various activities re- 
quired of endothelial cells in vivo during an angiogenic re- 
sponse. Of the common in vitro assays, the migration assay 
has  most consistently correlated  with in vivo angiogenic 
activity  (Folkman  and  Klagsbrun,  1987; Klagsbrun  and 
DAmore, 1991). As performed here it requires that endothe- 
lial cells digest their way through the gelatin that fills pores 
of a membrane and move to the other side of the membrane 
where a test compound has been placed. It measures the sum 
of chemokinesis and chemotaxis. TSP and the hamster 140- 
kD fragment inhibit both activities (Taraboletti et al., 1990; 
Rastinejad et al., 1989). All fragments and peptides of TSP1 
that blocked in vivo neovascularization in the rat cornea as- 
say also blocked endothelial cell migration in vitro. Intact 
TSP1, however, was inhibitory in vitro only at lower concen- 
trations. At high concentrations it stimulated migration (Fig. 
4), as has been observed by others (Taraboletti et al., 1990; 
1991). As previously shown by Taraboletti et al, (1990),  the 
stimulatory activity localized to the 25-kD heparin-binding 
domain and appeared in large part to be the result of activa- 
tion of random movement of endothelial ceils rather than of 
directed chemotaxis. The mechanism underlying this para- 
doxical effect of TSP1 has not been explored, but may relate 
to the ability of the heparin-binding domain to reverse focal 
adhesions formed by endothelial cells (Murphy-Ullrich and 
Hood,  1989;  Murphy-UUrich et al.,  1991). 
The data presented here localize the majority of the anti- 
angiogenic activity of the multidomain TSP1 protein to the 
central 70-kD stalk region of the  180-kD  subunit. This is 
consistent with the ability of the stalk to bind to endothelial 
cells (Dardik and Lahav, 1991) and with the ability of mono- 
clonal antibodies whose epitopes lie in the stalk region to 
block anti-angiogenic activity (Good et al., 1990).  The data 
presented cannot rigorously eliminate the possibility that 
some anti-angiogenic activity resides in the COOH-terminal 
cell-binding globular domain of TSP1 for it was not tested 
directly. However, two peptides from this region that show 
a high affinity for endothelial cells in cell attachment assays 
(Kosfeld, M. D., M. Finn, and W. A. Frazier, unpublished 
data) and thus might be expected to influence angiogenesis, 
were unable to inhibit endothelial cell migration (Tolsma, 
S.  S., and N. Bouck, unpublished data). 
The anti-angiogenlc stalk region of TSP1 contains three 
distinct domains each of which could play a role in blocking 
neovascularization. Anti-angiogenic activity has been iden- 
tiffed in two of these, the procollagen homology region and 
in the properdin-like repeat region 1. The third domain con- 
sists of three type 2 EGF-like repeats similar to those found 
in a wide variety of other molecules where they may serve 
to facilitate protein-protein interactions, respond to calcium 
or pH changes, or act as receptors in cell-cell communica- 
tion networks (Davis, 1990; Rebay et al., 1991). Our obser- 
vation that the 50/70-kD fragment of TSP1, in which half the 
molecules lack the EGF repeats, has an ED~o that is similar 
to that of  gpl40, which retains the EGF repeats, suggests that 
these  repeats  are  not  major  determinants  of  the  anti- 
angiogenic activity of the stalk region. Their activity can be 
tested when purified TSP3 and TSP4 proteins become avail- 
able, for they retain EGF repeat regions that are highly ho- 
mologous to those present in TSP1 and lack the procollagen 
homology  region  and  the  type  1  repeats  that  are  anti- 
angiogenic (Bornstein,  1992). 
Active TGF/3 copurifying with platelet TSP1 can be re- 
sponsible for up to 60% of the inhibitory activity of TSP1 
on  endothelial  cell  mitogenesis  (Murphy-Ullrich  et  al., 
1992). Our TSP preparations do contain some TGF/~ hence 
there was some concern that inhibition of in vitro assays for 
angiogenesis attributed to TSP1 and its fragments could be 
due to contaminating TGF/3. Previously published evidence 
argues against this possibility (summarized in Frazier, 1991) 
and is  supported by data presented here.  Antibodies that 
effectively neutralize TGFBI  failed to neutralize the inhibi- 
tory activity of TSP1 in migration assays or the activity of 
its 50/70-kD  fragment in [3H]thymidine  incorporation as- 
says.  Furthermore, synthetic peptides containing no TGFB 
reproduced the angiostatic effects of TSP1 in vitro and in 
vivo. 
TGF/3  induces  angiogenesis  in  several  in  vivo models 
(Rastinejad et al., 1989; Roberts and Sporn, 1989; Yang and 
Moses, 1990), yet when tested in vitro at nanomolar concen- 
trations, it blocks activities of endothelial cells usually cor- 
related with angiogenesis. This dichotomy has suggested that 
induction of angiogenesis in vivo by TGFB may be indirect 
and due to the release of angiogenic factors by inflammatory 
cells attracted by the TGF/3 (Roberts and Sporn, 1989).  But 
the bimodal dose-dependent effects of TGF~ on endothelial 
cell migration reported here suggest that at low doses of 
TGFB may be sfimulatory in the absence of accessory in- 
flammatory cells. Concentrations from 0.04-0.4 pM stimu- 
lated migration. Although this concentration is well below 
that at which TGF/5 affects a range of other biological activi- 
ties (5-35 pM, Cheifetz et al., 1988), similar low concentra- 
tions have been shown to induce the migration of monocytes 
(Wahl et al.,  1987) and of human fibroblasts (Postlethwaite 
et al., 1987),  and could be physiologically relevant in vivo. 
Anti-angiogenic activity was localized to two separate do- 
mains of TSP1. Peptides derived from type 1 repeats were 
able to block endothelial cell migration in vitro and neovas- 
cularization in vivo. These repeats contain adhesive domains 
that when adsorbed to plastic can mediate the adherence of 
a variety of cells (Prater et al.,  1991; Tuszynski, 1992) and 
when soluble can block cell-cell, celI-TSP, and TSP-heparin 
or  -sulfatide interactions  (Tuszynski,  1992;  Asch  et  al., 
1992; Guo et al., 1992). Peptide sequences from this region 
bind to a  receptor on a tumor cell line (Tuszynski et al., 
1993) and to the CD36 (GPIV) cell receptor (Asch et al., 
1992; Catimel et al., 1992), a molecule that has been shown 
to be present on endothelial cells derived from small vessels 
(Knowles et al., 1984; Swerlick et al., 1992) and is thought 
to serve as a receptor for TSP. Anti-angiogenic activity was 
found in peptides derived from the second and third type 1 
repeats, but not from the first repeat. This first repeat was 
also inactive as an attachment factor for human melanoma 
cells (Prater et al., 1991), although a shorter peptide derived 
from this same first type 1 repeat is active as an attachment 
factor for mouse melanoma cells (Tuszynski et al.,  1992). 
The  two active Mal  peptides  have  in  common a  central 
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Peptide  Source  Reference 
C D P G Y  I  G S R-NH2  Laminin  Sakamoto et al., 1991; 
Grant et al., 1989, 1992 
L Y  K K  I  I  K K L  L  E S  Platelet factor-4  Maione et al., 1990 
F C Y W K V C W  Somatostatin  Woltering et al., 1991 
F C F W K T  C T  Somatostatin  Woltering et al., 1991 
G R G D  Fibronectin,  others  Eijan et al., 1991 
SPWSSC*SVTC*GDGV  I  T  R  I  R  TSPMalII  This paper 
S  P W D  I  C*S V T  C*G G G V Q K R S K  TSP Malm  This paper 
N G V Q Y R N  TSP, procollagen region  This paper 
N I P P  I T C*V Q N G L R Y  Collagen I  This paper 
* see Table II. 
CSVTCG, but an 8-mer including these residues was inac- 
tive in migration assays, although a 6-mer nested within this 
peptide can block platelet aggregation (Tuszynski et al., 
1992; Asch et al., 1992).  Perhaps the stability of this short 
peptide is adequate for the platelet aggregation assay that is 
complete within minutes but insufficient for the three hour 
migration assays.  The two active Mal peptides also have in 
common the sequence GVXXR (Gly-Val-X-X-Arg) which is 
also present in all active Col peptides except pro(xl. The se- 
quence G/AVQ (Gly/Ala-Val-Gln) is present in the active Mal 
III and all active Col peptides but not in active Mal II. Addi- 
tional work is needed to clarify active residues within these 
peptides. Peptides able to block in vivo neovascularization 
have also been derived from molecules unrelated to TSP, see 
Table  VII.  No clear and informative homologies have yet 
been detected between these peptides and angioinhibitory 
peptides derived from TSP1. 
A series of peptides able to inhibit angiogenesis could also 
be derived from amino acid sequences present in the procol- 
lagen-like region of the central stalk of TSP1. These Col pep- 
tides appear to affect the endothelial cell differently than do 
the Mal peptides for their ability to block endothelial cell 
migration increased with and usually required the pretreat- 
ment of the cells with peptide, supporting a delayed mecha- 
nism of action.  A  peptide derived from the homologous 
NH~-terminal  propeptide  region  of  the  genuine  human 
procollagen I sequence was also inhibitory in vitro and in 
vivo.  The NH2-terminal propeptides that are cleaved from 
the prood chains of collagens I and III during maturation of 
the collagen fibril are able to specifically downregulate the 
production of prootl and pro(x2 chains of collagen I (Wiest- 
ner et al., 1979;  Paglia et al., 1979; Wu et al., 1986).  En- 
dothelial cells  do  synthesize collagen I  (Canfield et  al., 
1992a,b).  The perturbation of collagen synthesis can halt 
neovascularization (Ingber and Folkman, 1988)  and could 
provide a  delayed mechanism by which the Col peptides 
might inhibit angiogenesis. The finding that a peptide de- 
rived directly from human procollagen can block angiogene- 
sis raises the intriguing possibility that one of the in vivo 
functions of the NH2-terminal collagen propeptides liber- 
ated from developing fibrils of collagens I, III, and some- 
times II, is to depress angiogenesis. This would be consistent 
with high levels of NH2-terminal propeptide in tissues with 
limited angiogenic activity like developing bone and carti- 
lage (Fisher et al.,  1987; Ryan and Sandell, 1990). 
If data derived from peptides is to be relevant to the func- 
tion of the intact parental molecule, the regions containing 
the active residues must be exposed on the surface of the ma- 
ture molecule. Evidence that repeat region 1 from which the 
active Mal 1I and Malm peptides are derived is accessible 
to the environment is strong. Polyclonal antiserum raised to 
Mal II which recognizes Mal 11 and Mal 111 but not Mal I 
inhibits attachment of melanoma cells to TSP1, to the 50/70- 
kD stalk and to the peptides themselves (Prater et al., 1991). 
In addition, antibodies raised to the central residues in these 
peptides block platelet aggregation and platelet-dependent 
metastasis (Tuszynski, 1992). The availability of this region 
is consistent with biophysical studies on homologous regions 
of the properdin molecule that show each repeat consists of 
a  separately folded elongated beta sheet accessible to the 
aqueous environment (Smith et al., 1991, 1992).  Data sug- 
gesting that the procollagen-like region is exposed and active 
in the intact trimeric TSP1 molecule comes from the obser- 
vation  that  the  baculovirus-expressed  truncated  trimeric 
TSP-381  which carries the procollagen-like region but not 
the angioinhibitory properdin-like repeats is an active in- 
hibitor. 
It is not yet clear whether proteins encoded by other mem- 
bers  of the growing family of TSP genes can block neo- 
vascularization. Mouse TSP2 eDNA (Laherty et al., 1992; 
Bornstein, 1992) shows poor homology to TSP1 in the pro- 
collagen region, but good matches in the type 1 repeats. 
Residues contained in inhibitory Mal 1I and Mal 11I pep- 
tides are better conserved than those in inactive Mal I, but 
whether this represents conservation of TSP's role as a solid 
state attachment factor or as a soluble anti-angiogenic factor, 
or both is unclear. Type 1 repeats are also present in the neu- 
ral cell adhesion protein F-spondin, the newest TSP family 
member (Klar et al., 1992).  Both the type 1 repeats and the 
procollagen homology region are  absent from TSP3  and 
TSP4  (Lawler  et  al.,  1993;  Bornstein,  1992),  and  the 
thrombospondin-like protein, COMP (Oldberg et al., 1992). 
A number of mechanisms can be envisioned by which  TSP 
could act to limit an angiogenic response. (a) TSP1 and its 
peptides could interfere with positive angiogenic factors, se- 
questering or inactivating them,  or interfering with their 
binding to cells. Arguing against this possibility is the obser- 
vation that the TSP1 molecule and/or its 140-kD  hamster 
homologue can block angiogenesis induced in vivo by di- 
verse stimuli including bFGF, tumor necrosis factor, TGF/~, 
and  conditioned media  from  active  macrophages,  carci- 
noma, and sarcoma tumor cell lines (Rastinejad et al., 1989; 
Bouck, N., and P. J. Polverini, unpublished data). It seems 
unlikely that TSP1 could effectively sequester each of these 
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both of which block bFGF-induced angiogenesis, could both 
sequester bFGE (b) TSP might disrupt endothelial cell adhe- 
sion to  stroma thereby  blocking  migration.  This possibil- 
ity is rendered less likely by the observation that although 
the anti-adhesive activity of TSP1 has been localized to the 
heparin-binding domain (Murphy-Ullrich et al.,  1989), the 
isolated protein fragment carrying this activity,  the 25-kD 
fragment, was not inhibitory in our angiogenic assays. In ad- 
dition, the Mal peptides known to be adhesive for melanoma 
calls serve as very poor attachment factors for cultured capil- 
lary endothelial cells (Finn, M., and W. A. Frazier, unpub- 
lished data). (c) The proteolytic activity essential for neovas- 
cularization (Berman et al.,  1982; Avery et al.,  1990) could 
be sensitive to TSP inhibition. TSP binds plasminogen, plas- 
minogen activator and plasminogen activator inhibitor (Law- 
ler et al.,  1986; Silverstein et al.,  1986), and may influence 
plasmin activity (Hogg et al.,  1992). Plasminogen also binds 
to the 70-kD stalk fragment ofTSP (Lawler et al., 1986) that 
inhibits angiogenesis, but it is unknown if any of the active 
peptides from this fragment retain this activity and if the sum 
of such interactions enhance or inhibit proteolytic activity in 
vivo. (d) Many angioinhibitory molecules have in common 
the ability to block collagen synthesis or deposition (Ingber 
and Folkman,  1988;  Maragoudakis et al.,  1988),  and TSP 
may act similarly. It does bind collagens I, II, HI, and V, pos- 
sibly  via its procollagen-like  region  (Galvin  et al.,  1987; 
Frazier,  1987),  and  could  act  as  does  the  pro¢(1)  NHe- 
terminal peptide of collagen I (from which we could also de- 
rive an angioinhibitory  peptide)  to downregulate  collagen 
synthesis and thereby angiogenesis.  (e) TSP may bind to a 
receptor on endothelial cells, possibly via sequences present 
in repeat region 1 that can interact with CD36, producing an 
intracellular change that interferes with the positive signals 
generated by stimulatory angiogenic  factors.  The low con- 
centration at which both TSP and its peptides act supports 
such a receptor-mediated  mode of action. 
Testing each of these mechanisms should result in a clear 
understanding of how and possibly why two different struc- 
tural domains of TSP1 are able to influence a single physio- 
logical  function,  the  inhibition  of  neovascularization.  In 
addition, the definition of anti-angiogenic domains and pep- 
tides enables the design of molecules containing single do- 
mains that may express only one of TSP's many functions and 
thereby specifically block only the angiogenic process. Such 
targeted inhibitors could be of therapeutic use in combating 
pathological  conditions  from  vascular  disease  to  solid 
tumors that are dependent  upon unregulated  neovascular- 
ization. 
The  truncated  NHz-terminal  trimers  TSP-277  and  TSP-381  were  pro- 
duced and purified by J. Sottile and D. F. Mosher, University of Wiscon- 
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